Profile: Phibro Animal Health Corp (PAHC.A)
17 Jul 2019
Phibro Animal Health Corporation (Phibro), incorporated on January 27, 2014, is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products. The Company is focused on regions, which include the United States, Brazil, China, Russia, Mexico, Australia, Turkey, Israel, Canada and Europe. The Company also manufactures and markets specific ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries.
The Company's Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The Company's MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, Coxistac and amprolium. MFAs and other also includes antibacterial products used to control bacterial infections, as well as other processing aids, for the ethanol fermentation industry. Its MFA's products include Terramycin/TM-50/TM-100, Nicarb, amprolium, Bloat Guard, Banminth, Mecadox, Stafac/Eskalin/V-Max, Coxistac/Posistac, Rumatel, Cerditac/Cerdimix, Aviax/Aviax II, Neo-Terramycin/Neo-TM and Aviax Plus.
The Company's nutritional specialty products include OmniGen-AF and Animate. The Company sells OmniGen-AF in the United States, Canada, Mexico, Brazil and several European countries, Turkey, Israel, Japan, China and Australia. The Company sells Animate in the United States, Canada and Mexico. The Company sells Magni-Phi to poultry integrators in the United States. The Company's nutritional specialty also offers various products, which include AB20, Chromax, Biosaf, Procreatin 7, Animate, Safmannan, OmniGen-AF, Provia 6086 and Magni-Phi.
The Company's vaccines products are focused on preventing diseases in poultry and swine. The Company markets vaccines products in the United States, Israel, Turkey, China, South East Asia, India, East and Central Europe, Brazil and other Latin American countries and various African countries. The Company's vaccine products protect animals from both viral and bacterial disease challenges. As of June 30, 2016, the Company had developed and distributed over 25 vaccine presentations for prevention of disease in poultry, including vaccines to protect against Infectious Bursal Disease, Infectious Bronchitis, and Newcastle Disease. The Company's vaccines also offer various products, which include TAbic M.B., TAbic IB VAR, TAbic IB VAR206, V.H., MJPRRS and SRP Autogenous Vaccines.
The Company is the distributor of Epitopix's autogenous vaccines protecting against various diseases, including Salmonella and Escherichia coli (E. coli) for chickens in the United States, containing its SRP technology, primarily for broiler breeders and table egg laying hens. The Company's autogenous vaccines allow it to produce custom vaccines for veterinarians, which contain antigens specific to each farm, allowing Phibro to provide health management solutions to its customers.
The Company has developed TAbic, which is a delivery platform for vaccines. TAbic is a technology for formulation and delivery of vaccine antigens in effervescent tablets, packaged in sealed aluminum blister packages. Several of the Company's vaccine products are available in the TAbic format. The Company also focuses on producing new antigens or new presentations of antigens, and has developed new vaccines, such as the inactivated subunit Infectious Bursal Disease Virus and Egg Drop Syndrome vaccines, being sold as monovalent vaccines or in combinations with other antigens.
The Company manufactures active pharmaceutical ingredients for certain of its antibacterial and anticoccidial products at its facilities in Guarulhos, Brazil and Braganca Paulista, Brazil. The Company manufactures active pharmaceutical ingredients for certain of its anticoccidial products at its facility in Neot Hovav (formerly Ramat Hovav), Israel. The Company produces vaccines at its facilities in Beit Shemesh, Israel and Omaha, Nebraska. The Company produces pharmaceuticals, disinfectants and other animal health products at its facility in Petach Tikva, Israel. The Company produces certain nutritional specialty and mineral nutrition products at its facilities in Quincy, Illinois, and certain mineral nutrition products at its facility in Omaha, Nebraska.
Animal Health Segment
As of June 30, 2016, the animal health segment developed, manufactured and marketed more than 550 product presentations, including antibacterials, which inhibit the growth of pathogenic bacteria that cause bacterial infections in animals, anticoccidials, which inhibit the growth of coccidia (parasites) that damage the intestinal tract of animals, and related products (MFAs and other); nutritional specialty products, which manage nutrition to help improve health and performance (nutritional specialties), and vaccines, which cause an increase in antibody levels against a specific virus or bacterium, thus preventing infection from that viral or bacterial antigen (vaccines).
Mineral Nutrition Segment
As of June 30, 2016, the mineral nutrition segment manufactured and marketed more than 400 formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Its customers use these products to fortify the daily feed requirements of their livestock's diets and maintain an optimal balance of trace elements in each animal. The Company manufactures and markets mineral nutrition products for a range of food animals, including poultry, swine and beef, and dairy cattle.
The Performance Products segment manufactures and markets a number of specialty ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries, predominantly in the United States. The Company operates the performance products segment through its PhibroChem (a division of Phibro), Ferro Metal and Chemical Corporation Limited and Phibro-Tech, Inc. (Phibro-Tech) business units.
The Company competes with Bayer AG, Ceva Sante Animale, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Huvepharma Inc., Lallemand Inc., Merck & Co., Inc., Pharmgate LLC, Sanofi S.A., Southeastern Minerals, Inc., Virbac and Zoetis Inc.
Phibro Animal Health Corp
300 Frank W Burr Blvd Ste 21 Fl
TEANECK NJ 07666-6712